Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis.

Huang M, Tailor J, Zhen Q, Gillmor AH, Miller ML, Weishaupt H, Chen J, Zheng T, Nash EK, McHenry LK, An Z, Ye F, Takashima Y, Clarke J, Ayetey H, Cavalli FMG, Luu B, Moriarity BS, Ilkhanizadeh S, Chavez L, Yu C, Kurian KM, Magnaldo T, Sevenet N, Koch P, Pollard SM, Dirks P, Snyder MP, Largaespada DA, Cho YJ, Phillips JJ, Swartling FJ, Morrissy AS, Kool M, Pfister SM, Taylor MD, Smith A, Weiss WA.

Cell Stem Cell. 2019 Sep 5;25(3):433-446.e7. doi: 10.1016/j.stem.2019.05.013. Epub 2019 Jun 13.

2.

Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes.

Weishaupt H, Johansson P, Sundström A, Lubovac-Pilav Z, Olsson B, Nelander S, Swartling FJ.

Bioinformatics. 2019 Feb 1. doi: 10.1093/bioinformatics/btz066. [Epub ahead of print]

PMID:
30715209
3.

Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, Li G, Wechsler-Reya RJ, Reimand J, Cho YJ, Taylor MD, Weissman IL, Mitra SS, Cheshier SH.

Nat Commun. 2018 Nov 2;9(1):4651. doi: 10.1038/s41467-018-07182-1.

4.

Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity.

Wallmann T, Zhang XM, Wallerius M, Bolin S, Joly AL, Sobocki C, Leiss L, Jiang Y, Bergh J, Holland EC, Enger PØ, Andersson J, Swartling FJ, Miletic H, Uhrbom L, Harris RA, Rolny C.

iScience. 2018 Nov 30;9:71-83. doi: 10.1016/j.isci.2018.10.011. Epub 2018 Oct 16.

5.

LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.

Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom L.

J Pathol. 2019 Feb;247(2):228-240. doi: 10.1002/path.5186. Epub 2019 Jan 10.

PMID:
30357839
6.

Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, Li G, Wechsler-Reya RJ, Reimand J, Cho YJ, Taylor MD, Weissman IL, Mitra SS, Cheshier SH.

Nat Commun. 2018 Oct 8;9(1):4121. doi: 10.1038/s41467-018-06564-9. Erratum in: Nat Commun. 2018 Nov 2;9(1):4651.

7.

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.

Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJ.

Oncogene. 2018 May;37(21):2850-2862. doi: 10.1038/s41388-018-0135-1. Epub 2018 Mar 7.

8.

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M.

Brain. 2018 May 1;141(5):1300-1319. doi: 10.1093/brain/awy039.

PMID:
29490009
9.

Medulloblastoma: experimental models and reality.

Neumann JE, Swartling FJ, Schüller U.

Acta Neuropathol. 2017 Nov;134(5):679-689. doi: 10.1007/s00401-017-1753-3. Epub 2017 Jul 19. Review.

PMID:
28725965
10.

Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential.

Roy A, Libard S, Weishaupt H, Gustavsson I, Uhrbom L, Hesselager G, Swartling FJ, Pontén F, Alafuzoff I, Tchougounova E.

Front Oncol. 2017 Jun 2;7:115. doi: 10.3389/fonc.2017.00115. eCollection 2017.

11.

Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression.

Roy A, Attarha S, Weishaupt H, Edqvist PH, Swartling FJ, Bergqvist M, Siebzehnrubl FA, Smits A, Pontén F, Tchougounova E.

Oncotarget. 2017 Apr 11;8(15):24815-24827. doi: 10.18632/oncotarget.15820.

12.

Modeling and Targeting MYC Genes in Childhood Brain Tumors.

Hutter S, Bolin S, Weishaupt H, Swartling FJ.

Genes (Basel). 2017 Mar 23;8(4). pii: E107. doi: 10.3390/genes8040107. Review.

13.

Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence.

Suryo Rahmanto A, Swartling FJ, Sangfelt O.

Mol Cell Oncol. 2016 Nov 8;4(1):e1252871. doi: 10.1080/23723556.2016.1252871. eCollection 2017.

14.

Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype.

Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S, Alafuzoff I, Weishaupt H, Fryknäs M, Larsson R, Swartling FJ, Uhrbom L.

Cancer Res. 2017 Feb 1;77(3):802-812. doi: 10.1158/0008-5472.CAN-16-2482. Epub 2016 Nov 15.

15.

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.

Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, Rosén G, Čančer M, Hutter S, Sundström A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Cho YJ, Pfister SM, Kool M, Korshunov A, Swartling FJ, Sangfelt O.

EMBO J. 2016 Oct 17;35(20):2192-2212. Epub 2016 Sep 13.

16.

Utilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development-Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus.

Truvé K, Dickinson P, Xiong A, York D, Jayashankar K, Pielberg G, Koltookian M, Murén E, Fuxelius HH, Weishaupt H, Swartling FJ, Andersson G, Hedhammar Å, Bongcam-Rudloff E, Forsberg-Nilsson K, Bannasch D, Lindblad-Toh K.

PLoS Genet. 2016 May 12;12(5):e1006000. doi: 10.1371/journal.pgen.1006000. eCollection 2016 May.

17.

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.

Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud FI, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Ellison DW, Wharton SB, Robson K, Michalski A, Hargrave D, Jacques TS, Pizer B, Bailey S, Swartling FJ, Weiss WA, Chesler L, Clifford SC.

Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014 Dec 18.

18.

Deregulated proliferation and differentiation in brain tumors.

Swartling FJ, Čančer M, Frantz A, Weishaupt H, Persson AI.

Cell Tissue Res. 2015 Jan;359(1):225-54. doi: 10.1007/s00441-014-2046-y. Epub 2014 Nov 23. Review.

19.

BET bromodomain inhibition of MYC-amplified medulloblastoma.

Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, Cheshier SH, Qi J, Liu KW, Wechsler-Reya R, Weiss WA, Swartling FJ, Kieran MW, Bradner JE, Beroukhim R, Cho YJ.

Clin Cancer Res. 2014 Feb 15;20(4):912-25. doi: 10.1158/1078-0432.CCR-13-2281. Epub 2013 Dec 2.

20.

Signals that regulate the oncogenic fate of neural stem cells and progenitors.

Swartling FJ, Bolin S, Phillips JJ, Persson AI.

Exp Neurol. 2014 Oct;260:56-68. doi: 10.1016/j.expneurol.2013.01.027. Epub 2013 Jan 31. Review.

Supplemental Content

Loading ...
Support Center